EP2491040A2 - Method of preparing sitagliptin and intermediates used therein - Google Patents
Method of preparing sitagliptin and intermediates used thereinInfo
- Publication number
- EP2491040A2 EP2491040A2 EP10825169A EP10825169A EP2491040A2 EP 2491040 A2 EP2491040 A2 EP 2491040A2 EP 10825169 A EP10825169 A EP 10825169A EP 10825169 A EP10825169 A EP 10825169A EP 2491040 A2 EP2491040 A2 EP 2491040A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- mixture
- group
- trifluorophenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to a novel method of preparing sitagliptin, and intermediates used therein.
- Sitagliptin phosphate is a selective inhibitor of the second generation dipeptidyl peptidase IV (DPP-4) and used to maintain the systemic concentration of incretin hormone at an optimum level.
- Sitagliptin phosphate monohydrate was approved in October 2006 by the US Food and Drug Administration (FDA) as an adjuvant in dietetics or kinesiatrics for treatment of patients with type-2 diabetes and it is marketed in the United States and Korea under the trade name of JANUVIATM (as a single agent).
- FDA US Food and Drug Administration
- Boc is tert-butoxycarbonyl
- TEA is trimethylamine
- HOBt is 1- hydroxybenzotriazole
- EDC is N-ethyl-N'-(3- dimethylaminopropyl)carbodiimide
- DIPEA is N,N-diisopropylethylamine.
- BINAP is 2,2'-bis(diphenylphosphino)-l,l'-binaphthyl
- EDC is N-ethyl-N'-(3- dimethylaminopropyl)carbodiimide
- Bn is benzyl
- DIAD is diisopropyl azodicarboxylate
- NMM is N-methylmorpholine
- ACN is acetonitrile.
- WO 2005/097733 discloses a method for preparing sitagliptin by stereoselectively reducing an enamine employing a rhodium-based catalyst, [Rh(cod)Cl] 2 having a chiral diphosphine ligand, as shown in Reaction Scheme 4.
- sitagliptin can be prepared by a simple and low-cost method using a chiral oxirane prepared from the commercially available epichlorohydrin.
- sitagliptin of formula (I) which comprises the steps of:
- the method of preparing sitagliptin according to the present invention is characterized by the use of chiral oxirane, which has commercially available (S) or (R) isomer form in order to prepare the sitagliptin at a low cost.
- the present invention provides the method of preparing sitagliptin which comprises the steps of: (i) allowing (S)-epichlorohydrin to undergo arylation, epoxidation, and vinylation reactions to obtain (2R)-l-(2,4,5-trifluorophenyl)-4-pentene-2-ol of formula (II);
- Sitagliptin of formula (I) of the present invention may be prepared by the procedure shown in Reaction Scheme 5.
- step (i) (S)-epichlorohydrin is subjected to undergo arylation, epoxidation, and vinylation reactions, successively, to obtain (2R)-l-(2,4,5- trifluorophenyl)-4-pentene-2-ol of formula (II).
- the Grignard reagent is mixed with a catalytic amount of a copper halide (CuX), and then (S)-epihalohydrin is added thereto slowly at a low temperature for arylation to obtain (2S)-3-(2,4,5-trifluorophenyl)-l-chloro - 2-propanol (Step ia).
- CuX copper halide
- the Grignard reagent may be prepared by treating 2,4,5- trifluorobenzene halide with magnesium (Mg) and organic halide alkyl (e.g., 1,2-dibromoethane); Mg and I 2 ; or isopropyl magnesium chloride ( -PrMgCl).
- Mg magnesium
- organic halide alkyl e.g., 1,2-dibromoethane
- I 2 e.g., 1,2-dibromoethane
- -PrMgCl isopropyl magnesium chloride
- the 2,4,5-trifluorobenzene halide may be selected from the group consisting of 2,4,5-trifluorobenzene bromide, 2,4,5-trifluorobenzene chloride, and a mixture thereof.
- the oxirane such as (S)-epichlorohydrin comprises (S) or (R) isomer, which is commercially available.
- the copper halide may be selected from the group consisting of Cul, CuBr, CuBrS(CH 3 ) 2 , and a mixture thereof.
- the solvent used in this reaction may be tetrahydrofuran, diethyl ether and the like.
- the strong base used in this reaction may be an alkali metal hydroxide such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and a mixture thereof, and preferably, sodium hydroxide.
- (2S)-2-(2,4,5-trifluorobenzyl)-oxirane thus obtained subjected to a vinylation reaction using vinylmagnesium halide in the presence of a catalytic amount of copper halide to selectively introduce the vinyl group at the terminal position, to obtain (2R)-l-(2,4,5-trifluorophenyl)-4-penten-2-ol of formula (II) (Step ic).
- the copper halide may be selected from the group consisting of Cul, CuBr, CuBrS(CH 3 ) 2 , and a mixture thereof.
- the vinylmagnesium halide may be selected from the group consisting of vinylmagnesium bromide, vinylmagnesium chloride, and a mixture thereof.
- reaction carried out in a solvent such as tetrahydrofuran, diethyl ether and the like.
- step (ii) (2R)-l-(2,4,5-trifluorophenyl)-4-penten-2-ol of formula (II) obtained in step (i) is reacted with an activator having methansulfonyl or tosyl group to activate the hydroxyl group. Then, the resulting compound may be conducted to azidation for introducing the azido group to obtain (2S)-l-(2- azido-4-pentenyl)-2,4,5-trifluorobenzene of formula (III).
- the activator used in this reaction may be selected form the group consisting of mesyl chloride, p-tosyl chloride, bezenesulfonyl chloride, trifluoromethansulfonyl chloride, and a mixture thereof which has methansulfonyl or tosyl group.
- the azidation is conducted using a compound having the azido group such as sodium azide, preferably.
- step (iii) (2S)-l-(2-azido-4-pentenyl)-2,4,5-trifluorobenzene of formula (III) obtained in step (ii) is allowed to oxidize the alkenyl group of the compound of formula (III) in the presence of an oxidant and introduce carboxyl group to obtain (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid of formula (IV).
- the oxidant used in this reaction may be selected from the group consisting of NaIO 4 , NaMnO 4 , KMnO 4 , H 2 CrO 4 , OsO 4 , NaOCl, and a mixture thereof.
- the oxidant may be used in an amount of 1 to 5 equivalents based on the compound of formula (III).
- the step (iii) is preferably carried out in presence of a catalyst.
- the catalyst may be selected from the group consisting of RuCl 3 , RuO 4 , OsO 4 , KMnO 4 , and a mixture thereof.
- the catalyst may be used in an amount of 0.0001 to 0.1 equivalents based on the compound of formula (III).
- step (iv) (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid of formula (IV) obtained in step (iii) is subjected to a condensation reaction with a triazol derivative of formula (VI) to obtain (3R)-3-azido-l-(3-trifluoromethyl)- 5,6-dihydro-8H-[l,2,4]triazolo[4,3-a]pyrazin-7-yl)-4-(2,4,5-trifluorophenyl)- butan-l-one of formula (V).
- (3R)-3-azido-4-(2,4,5- trifluorophenyl)-butyric acid of formula (IV) is treated with carboxyl group activator to activate the carboxyl group.
- the carboxyl group activator may be selected from the group consisting of N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide (EDC), ⁇ , ⁇ '- dicyclohexylcarbodiimide (DCC), ⁇ , -carbonyldiimidazol (CDI), a mixture of DCC and 1-hydroxybenzotriazole (HOBt), a mixture of DCC and 1- hydroxy succinimide, and a combination thereof.
- EDC N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide
- DCC dicyclohexylcarbodiimide
- CDI ⁇ , -carbonyldiimidazol
- HOBt 1-hydroxybenzotriazole
- step (v) the azido group of compound of formula (V) obtained in step (iv) is reduced to obtain sitagliptin of formula (I).
- the reductant may be a mixture of PPh 3 and H 2 O, a mixture of PPh 3 and HCl, a mixture of PPh 3 and NH 4 OH, a mixture of PPh 3 and H 2 S, and the like.
- the reductant may be hydrogen, HCOOH, (NH 4 )O 2 H, NH 2 NH 2 , BH 3 , NaBH 4 , a mixture of Zn and HCl, and a combination thereof, in the presence of a metallic catalyst such as Raney Ni, Pd, Pt, Pd/C, Pd/Al 2 O 3 , Pd(OH) 2 /C, a combination thereof and the like.
- the high yield of sitagliptin can be prepared by a simple and a low cost method, which has not been achieved in the prior art.
- the present invention provides novel compounds, (2R)-1 -(2,4,5- trifluorophenyl)-4-penten-2-ol of formula (II), (2S)-l-(2-azido-4-pentenyl)- 2,4,5-trifluorobenzene of formula (III), (3R)-3-azido-4-(2,4,5-trifluorophenyl)- butyric acid of formula (IV) and (3R)-3-azido-l-(3-trifluoromethyl)-5,6- dihydro-8H-[l,2,4]triazolo[4,3-a]pyrazin-7-yl)-4-(2,4,5-trifluorophenyl)-butan- 1-one of formula (V), which are the key intermediates used in the present invention.
- Step 1 Preparation of (2S)-3-(2A5-trifluorophenyl)-l-chloro-2-propanol
- Step 1 Preparation of (2S)-3-(2A5-trifluorophenyl)-l-chloro-2-propanol
- Step 2 Preparation of (2S)-2-(2,4,5-trifluorobenzyl)-oxirane (2S)-3-(2,4,5-trifluorophenyl)-l-chloro-2-propanol obtained in step 1 was dissolved in 50 ml of methanol, and NaOH (2.3 g) was added dropwise thereto. A mixture was stirred for 1 hour, and methanol was removed therefrom under a reduced pressure. Water (50 ml) and ethyl acetate (50 ml) were added thereto, and the organic layer formed thereafter was separated. The separated organic layer was washed with satuated saline, dried over MgSO 4 , and filtered to remove MgSO 4 . The organic solvent was removed from the filtrate under a reduced pressure to obtain the title compound (7.6 g; yield: 85%).
- Example 1 Preparation of Sitagliptin
- the organic solvent was removed from the filtrate under a reduced pressure.
- the residue thus obtained was dissolved in DMF (300 ml), and NaN 3 (9.91 g) was added thereto.
- the resulting mixture was heated to 70 °C , stirred for 2 hours, and cooled to room temperature. And then water (150 ml) and ethyl acetate (150 ml) were added to the resulting mixture, and the organic layer formed thereafter was separated.
- the organic layer was washed twice with 150 ml of satuated saline, dried over MgSO 4 , and filtered.
- the organic solvent was removed from the filtrate under a reduced pressure to obtain the title compound (31.5 g; yield: 94%).
- Acetonitril (300 ml) and water (300 ml) were added to the (2S)-l-(2- azido-4-pentenyl)-2,4,5-trifluorobenezene obtained in step 2, and cooled to 0°C .
- RuCl 3 (0.5 g) and NaIO 4 (93 g) were added to the mixture successively, and stirred for 5 hours.
- Ethyl acetate (90 ml) was added to the resulting mixture, filtered and the organic layer formed thereafter was separated.
- Step 4 Preparation of (3R)-3-azido-l-(3-trifluoromethyl-5,6-dihydro-8H- [ 1 ,2,41triazolor4,3-alpyrazin-7-yl)-4-(2,4,5-trifluorophenyl)-butan- 1 -one
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090100336A KR101222679B1 (en) | 2009-10-21 | 2009-10-21 | Method of preparing sitagliptin and intermediates used therein |
PCT/KR2010/007150 WO2011049344A2 (en) | 2009-10-21 | 2010-10-19 | Method of preparing sitagliptin and intermediates used therein |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2491040A2 true EP2491040A2 (en) | 2012-08-29 |
EP2491040A4 EP2491040A4 (en) | 2013-05-22 |
Family
ID=43900806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10825169.5A Withdrawn EP2491040A4 (en) | 2009-10-21 | 2010-10-19 | Method of preparing sitagliptin and intermediates used therein |
Country Status (12)
Country | Link |
---|---|
US (1) | US8624026B2 (en) |
EP (1) | EP2491040A4 (en) |
JP (1) | JP2013508355A (en) |
KR (1) | KR101222679B1 (en) |
CN (1) | CN102574862A (en) |
AR (1) | AR078682A1 (en) |
AU (1) | AU2010308758B2 (en) |
CA (1) | CA2776407C (en) |
IL (1) | IL219278A0 (en) |
SA (1) | SA110310794B1 (en) |
TW (1) | TWI421253B (en) |
WO (1) | WO2011049344A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101156587B1 (en) * | 2010-02-19 | 2012-06-20 | 한미사이언스 주식회사 | Preparation method of sitagliptin and amine salt intermediate used therein |
EP2625179A2 (en) * | 2010-10-08 | 2013-08-14 | Cadila Healthcare Limited | Process for preparing an intermediate of sitagliptin via enzymatic conversion |
WO2012148246A2 (en) * | 2011-04-29 | 2012-11-01 | Daewoong Pharmaceutical Co., Ltd. | A preparation method of sitagliptin |
AU2012277403A1 (en) | 2011-06-30 | 2014-01-30 | Ranbaxy Laboratories Limited | Novel salts of sitagliptin |
WO2013065066A1 (en) | 2011-11-02 | 2013-05-10 | Cadila Healthcare Limited | Processes for preparing 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro [l,2,41-triazolo[43-a]pyrazin-7(8h)-yl]-l-(2,4,5- trifluorophenyl)butan-2-amine |
US20140350023A1 (en) | 2011-12-08 | 2014-11-27 | Ranbaxy Laboratories Limited | Amorphous form of sitagliptin salts |
CN102627648B (en) * | 2012-04-14 | 2014-11-12 | 江苏施美康药业股份有限公司 | Preparation method of sitagliptin |
KR20150056541A (en) | 2012-08-08 | 2015-05-26 | 시플라 리미티드 | Process for the preparation of sitagliptin and intermediate compounds |
IN2013MU00916A (en) * | 2013-03-20 | 2015-06-26 | Cadila Healthcare Ltd | |
IN2014MU00212A (en) * | 2014-01-21 | 2015-08-28 | Cadila Healthcare Ltd | |
CN106146514B (en) * | 2015-04-15 | 2020-01-10 | 浙江九洲药业股份有限公司 | Intermediate for preparing sitagliptin and preparation method and application thereof |
CN105017081B (en) * | 2015-07-08 | 2017-03-08 | 和鼎(南京)医药技术有限公司 | A kind of preparation method of sitagliptin intermediate |
CN105017099B (en) * | 2015-07-15 | 2017-03-22 | 成都千禧莱医药科技有限公司 | Sitagliptin chiral intermediate and asymmetric synthesis method thereof |
CN104987338B (en) * | 2015-07-30 | 2017-07-21 | 新发药业有限公司 | A kind of preparation method of Sitagliptin phosphate key intermediate |
CN109928888B (en) * | 2017-12-19 | 2023-04-11 | 浙江瑞博制药有限公司 | Preparation method of sitagliptin intermediate |
CN108586346B (en) | 2018-05-10 | 2019-10-01 | 北京富盛嘉华医药科技有限公司 | A kind of method that biocatalysis synthesizes sitagliptin and its intermediate |
CN113511984B (en) * | 2020-04-10 | 2022-10-11 | 中国科学院福建物质结构研究所 | Preparation method and application of beta-azido acid and beta-amino acid compound |
CN113773323B (en) * | 2020-06-10 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | Preparation method of 3R-amino substituted butyramide derivative |
CN111718353B (en) * | 2020-08-04 | 2023-02-10 | 许昌恒生制药有限公司 | Preparation method of sitagliptin phosphate |
CN112194576A (en) * | 2020-10-13 | 2021-01-08 | 台州市生物医化产业研究院有限公司 | Sitagliptin key intermediate impurity and preparation method and application thereof |
KR102589305B1 (en) * | 2021-04-22 | 2023-10-16 | 주식회사 메디켐코리아 | Improved manufacturing method of sitagliptin phosphate salt |
CN115819260B (en) * | 2022-11-28 | 2024-03-19 | 江苏阿尔法药业股份有限公司 | Synthesis process of sitagliptin intermediate |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010122578A2 (en) * | 2009-04-20 | 2010-10-28 | Msn Laboratories Limited | Process for the preparation of sitagliptin and its intermediates |
EP2397141A1 (en) * | 2010-06-16 | 2011-12-21 | LEK Pharmaceuticals d.d. | Process for the synthesis of beta-amino acids and derivatives thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR043515A1 (en) | 2003-03-19 | 2005-08-03 | Merck & Co Inc | PROCEDURE TO PREPARE CHIRAL DERIVATIVES BETA AMINO ACIDS BY ASYMMETRIC HYDROGENATION |
WO2004085661A2 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc | Process to chiral beta-amino acid derivatives |
WO2004087650A2 (en) | 2003-03-27 | 2004-10-14 | Merck & Co. Inc. | Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors |
CN101357921B (en) * | 2007-08-02 | 2011-01-12 | 山东轩竹医药科技有限公司 | New dipeptidase-IV inhibitor compound |
WO2009084024A2 (en) | 2007-11-02 | 2009-07-09 | Glenmark Generics Limited | A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof |
CA2707790C (en) | 2007-12-20 | 2015-04-21 | Dr. Reddy's Laboratories Limited | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof |
CN101429115B (en) * | 2008-12-22 | 2012-06-13 | 浙江海翔药业股份有限公司 | Process for producing trifluoro benzene acetic acid and sitagliptin |
-
2009
- 2009-10-21 KR KR1020090100336A patent/KR101222679B1/en not_active IP Right Cessation
-
2010
- 2010-10-19 WO PCT/KR2010/007150 patent/WO2011049344A2/en active Application Filing
- 2010-10-19 JP JP2012535120A patent/JP2013508355A/en active Pending
- 2010-10-19 EP EP10825169.5A patent/EP2491040A4/en not_active Withdrawn
- 2010-10-19 US US13/502,260 patent/US8624026B2/en not_active Expired - Fee Related
- 2010-10-19 CA CA2776407A patent/CA2776407C/en not_active Expired - Fee Related
- 2010-10-19 CN CN2010800472854A patent/CN102574862A/en active Pending
- 2010-10-19 AU AU2010308758A patent/AU2010308758B2/en not_active Expired - Fee Related
- 2010-10-20 TW TW099135733A patent/TWI421253B/en not_active IP Right Cessation
- 2010-10-20 AR ARP100103823A patent/AR078682A1/en not_active Application Discontinuation
- 2010-10-23 SA SA110310794A patent/SA110310794B1/en unknown
-
2012
- 2012-04-19 IL IL219278A patent/IL219278A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010122578A2 (en) * | 2009-04-20 | 2010-10-28 | Msn Laboratories Limited | Process for the preparation of sitagliptin and its intermediates |
EP2397141A1 (en) * | 2010-06-16 | 2011-12-21 | LEK Pharmaceuticals d.d. | Process for the synthesis of beta-amino acids and derivatives thereof |
Non-Patent Citations (3)
Title |
---|
AHN ET AL: "Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 9, 3 April 2007 (2007-04-03), pages 2622-2628, XP022015357, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.01.111 * |
NAIDU ET AL: "A simple and efficient approach to 1,3-aminoalcohols: application to the synthesis of (+)-negamycin", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 48, no. 22, 3 May 2007 (2007-05-03), pages 3793-3796, XP022058982, ISSN: 0040-4039, DOI: 10.1016/J.TETLET.2007.03.169 * |
See also references of WO2011049344A2 * |
Also Published As
Publication number | Publication date |
---|---|
TW201124419A (en) | 2011-07-16 |
EP2491040A4 (en) | 2013-05-22 |
IL219278A0 (en) | 2012-06-28 |
AU2010308758A1 (en) | 2012-06-14 |
SA110310794B1 (en) | 2013-12-01 |
KR101222679B1 (en) | 2013-01-16 |
WO2011049344A3 (en) | 2011-10-13 |
JP2013508355A (en) | 2013-03-07 |
US20120214997A1 (en) | 2012-08-23 |
TWI421253B (en) | 2014-01-01 |
AR078682A1 (en) | 2011-11-23 |
KR20110043288A (en) | 2011-04-27 |
AU2010308758B2 (en) | 2014-03-06 |
WO2011049344A2 (en) | 2011-04-28 |
CA2776407A1 (en) | 2011-04-28 |
CA2776407C (en) | 2013-10-01 |
CN102574862A (en) | 2012-07-11 |
US8624026B2 (en) | 2014-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010308758B2 (en) | Method of preparing sitagliptin and intermediates used therein | |
EP2481722B1 (en) | Sitagliptin intermediates, preparation methods and uses thereof | |
EP2609099A2 (en) | Sitagliptin, salts and polymorphs thereof | |
JP7377828B2 (en) | Method for preparing pyrimidinylcyclopentane compounds | |
US20110130378A1 (en) | Ezetimibe process and composition | |
KR101156587B1 (en) | Preparation method of sitagliptin and amine salt intermediate used therein | |
WO2015172732A1 (en) | Aminotetrahydropyran derivative used as dipeptidyl peptidase-iv inhibitor | |
CN1268611C (en) | Method of preparing 4-hydroxy pyrrolidone-2-acetamine | |
AU2002331163B2 (en) | Process for the Preparation of a 14-hydroxynormorphinone Compound | |
CN102378751B (en) | Improved method for preparing dipeptidyl peptidase-iv inhibitor and intermediate | |
CN102378752A (en) | Improved method for manufacturing dipeptidyl peptidase-iv inhibitor and intermediate | |
EP2471775B1 (en) | Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor | |
WO2011040717A2 (en) | Method for preparing intermediate of sitagliptin using chiral oxirane | |
KR101177821B1 (en) | Method for preparing intermediate of sitagliptin and intermediates used therein | |
CN103254120B (en) | Spiro-azasugar quaternary ammonium salt compound, and preparation method and application thereof | |
CN105254519A (en) | Synthesizing method of sitagliptin key intermediate | |
JPH0776588A (en) | P-boronophenylalanine derivative, production thereof and intermediate compound for the same derivative | |
JPH09249681A (en) | 6-0-(2-acetamidoethylphosphonyl)-d-mannopyranoside derivative and its production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120518 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HANMI SCIENCE CO., LTD. |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130424 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/4985 20060101ALI20130418BHEP Ipc: C07D 487/02 20060101ALI20130418BHEP Ipc: C07D 487/04 20060101AFI20130418BHEP Ipc: A61P 3/10 20060101ALI20130418BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20131126 |